
|Articles|May 1, 2004
Microplasmin receives orphan drug protection
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
2
FDA guidance to help accelerate cell and gene therapies
3
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
4
The Residency Report: Cardiovascular risk scores as a window into ocular disease
5





















